Summary
Rheumatic heart disease remains a major problem in developing countries, as it occurs early in life and in severe form. Apart from the well-recognised aetiological factors of poverty and overcrowding, increased virulence of the infecting streptococci and antigenic crossreactivity between streptococcal M protein and cardiac tissue have also been implicated.
The following factors all point to a strong likelihood of genetic susceptibility in affected individuals: (a) an association with human leucocyte (HLA) antigens at the D locus; (b) an association with particular alloantigens on B lymphocytes; (c) heightened responsiveness of T cells to stimulation with streptococcal polysaccharide; and (d) increased avidity for adherence of rheumatogenic streptococci to mucosal cells in the pharynx. Altered cell-mediated immunity also appears to be implicated.
Penicillin prophylaxis is the mainstay of prevention. To overcome problems such as noncompliance, a national computer register of all patients with the disease is desirable in countries whose health budgets would allow this, together with intensive continuing health education of both health workers and the general public and the issuing of patient-carried identification cards to those receiving continuous prophylaxis.
Similar content being viewed by others
References
Agarwal BL. Rheumatic heart disease unabated in developing countries. Lancet 1981; 2: 910–1
McLaren MJ, Hawkins DM, Koornhof HJ, et al. Epidemiology of rheumatic heart disease in black children of Soweto, Johannesburg. BMJ 1975; 3: 474–7
Padmavati S. Rheumatic fever and rheumatic heart disease in developing countries. Bull World Health Organ 1978; 56: 543–50
Jaiyesimi F. Acquired heart disease in Nigerian children: an illustration of the influence of socio-economic factors on disease pattern. J Trop Pediatr 1982; 28: 223–9
Strasser T, Rotta J. The control of rheumatic fever and rheumatic heart disease: an outline of WHO activities. WHO Chron 1973; 27: 49–54
Mathur KS. Rheumatic heart disease — problems and promises. J Assoc Physicians India 1976; 24: 373–82
Padmavati S. Epidemiology of cardiovascular disease in India. Rheumatic heart disease. Circulation 1962; 25: 703–7
Haffejee IE, Hammond MG, Moosa A. HLA antigens in black South African children with rheumatic heart disease. Ann Trop Paediatr 1982; 2: 17–22
John S, Krishnaswami S, Jairaj PS, et al. The profile and management of mitral stenosis in young patients. J Thorac Cardiovasc Surg 1975; 69: 631–8
Beg MH, Reyazuddin. Mitral stenosis in childhood and adolescence — a study of 45 cases and their surgical management. Ann Trop Pediatr 1989; 9: 98–101
Gordis L. The virtual disappearance of rheumatic fever in the United States: lessons in the rise and fall of disease. Circulation 1985; 72: 1155–62
Markowitz M. The decline of rheumatic fever: role of medical intervention. J Pediatr 1985; 106: 545–50
Massell BF, Chute CG, Walker AM, et al. Penicillin and the marked decrease in morbidity and mortality from rheumatic fever in the United States. N Engl J Med 1988; 318: 280–5
Wald ER, Dashefsky B, Feidt C, et al. Acute rheumatic fever in Western Pennysylvania and the tristate area. Pediatrics 1987; 80: 371–4
Hosier DM, Craenen JM, Teske DW, et al. Resurgence of acute rheumatic fever. Am J Dis Child 1987; 141: 730–3
Congeni B, Rizzo C, Congeni J, et al. Outbreak of acute rheumatic fever in northeast Ohio. J Pediatr 1987; 111: 176–9
Westlake RM, Graham TP, Edwards KM. An outbreak of acute rheumatic fever in Tennessee. Pediatr Infect Dis J 1990; 9: 97–100
Bisno AL. The resurgence of acute rheumatic fever in the United States. Annu Rev Med 1990; 41: 319–29
Veasy LG, Wiedmeier SE, Orsmond GS, et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med 1987; 316: 421–7
Bonora G, Rogari P, Acerbi L, et al. Outbreak of acute rheumatic fever in northern Italy. J Pediatr 1989; 114: 334
Goldstein I, Halpern B, Robert L. Immunologic relationship between streptococcus A polysaccharide and the structural glycoprotein of heart valve. Nature 1967; 213: 44–7
Dudding BA, Ayoub EM. Persistence of streptococcal Group A antibody in patients with rheumatic valvular disease. J Exp Med 1968; 128: 1081–98
Shulman ST, Ayoub EM, Victorica BE, et al. Differences in antibody response to streptococcal antigens in children with rheumatic and non-rheumatic mitral valve disease. Circulation 1974; 50: 1244–51
Appleton RS, Victorica BE, Tamer D, et al. Specificity of persistence of antibody to the streptococcal Group A carbohydrate in rheumatic valvular disease. J Lab Clin Med 1985; 105: 114–9
Markowtiz M, Gordis L. The biology of group A beta hemolytic streptococci. In: Rheumatic fever. 2nd ed. Philadelphia: WB Saunders Co, 1972: 14–22
Kaplan EL, Johnson DR, Cleary PP. Group A streptococcal/ serotypes isolated from patients and sibling contacts during the resurgence of rheumatic fever in the United States in the mid-1980s. J Infect Dis 1989; 159: 101–3
Wannamaker LW. Differences between streptococcal infections of the throat and of the skin. N Engl J Med 1970; 282: 23–31
Wannamaker LW. Differences between streptococcal infections of the throat and of the skin. N Engl J Med 1970; 282: 78–85
Dillon HC. Streptococcal skin infections and glomerulonephritis. In: Hoeprich PD, Jordan MC, editors. Infectious diseases: a treatise of infectious processes. 4th ed. Philadelphia: JB Lippincott Co, 1989: 995–1000
Majeed HA, Khuffash FA, Yousof AM, et al. The rheumatogenic and nephritogenic strains of the group A streptococcus: the Kuwait experience. NZ Med J 1988; 101: 398–401
Beachey EH, Seyer JM, Dale JB, et al. Type-specific protective immunity evoked by synthetic peptide of Streptococcus pyogenes M protein. Nature 1981; 292: 457–9
Dale JB, Beachey EH. Epitopes of streptococcal M proteins shared with cardiac myosin. J Exp Med 1985; 162: 583–91
Cunningham MW, Krisher K, Graves D. Murine monoclonal antibodies reactive with human heart and Group A streptococcal membrane antigens. Infect Immun 1984; 46: 34–41
Cunningham MW, McCormack JM, Talaber LR, et al. Human monoclonal antibodies reactive with antigens of the Group A streptococcus and human heart. J Immunol 1988; 141: 2760–6
Dale JB, Beachey EH. Protective antigenic determinant of streptococcal M protein shared with sarcolemmal membrane protein of human heart. J Exp Med 1982; 156: 1165–76
Baird RW, Bronze MS, Kraus W, et al. Epitopes of group A streptococcal M protein shared with antigens of articular cartilage and synovium. J Immunol 1991; 146: 3132–7
Husby G, Van der Rijn U, Zabriskie JB, et al. Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med 1976; 144: 1094–110
Ofek I, Beachey EH, Jefferson W, et al. Cell membrane-binding properties of Group A streptococcal lipoteichoic acid. J Exp Med 1975; 141: 990–1033
Beachey EH. Bacterial adherence: adhesin-receptor interactions mediating the attachment of bacteria to mucosal surfaces. J Infect Dis 1981; 143: 325–45
Myhre EB, Kronvall G. Immunoglobulin specificities of defined types of streptococcal Ig receptors. In: Holm SE, Christensen P, editors. Basic concepts of streptococci and streptococcal diseases. Chertsey: Redbook Ltd, 1981: 209–10
Reis KJ, Ayoub EM, Boyle MDP. Detection of receptors of Fc region of IgG on streptococci. J Immunol Methods 1983; 59: 83–94
Gray ED. Nucleases of group A streptococci. In: Wannamaker LW, Matsen JM, editors. Streptococci and streptococcal diseases. New York: Academic Press, 1972: 143–55
Thompson A, Halbert SP, Smith U. The toxicity of streptolysin O for beating mammalian heart cells in tissue culture. J Exp Med 1970; 131: 745–63
Hirschhorn K, Schreibman RR, Verbo S, et al. The action of streptolysin S on peripheral lymphocytes of normal subjects and patients with acute rheumatic fever. Proc Natl Acad Sci USA 1964; 52: 1151–7
Kim YB, Watson DW. Streptococcal exotoxins: biological and pathological properties. In: Wannamaker LW, Matsen JM, editors. Streptococci and streptococcal diseases. New York: Academic Press, 1972: 33–50
Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321: 1–7
Belani K, Schlievert PM, Kaplan EL, et al. Association of exotoxin-producing group A streptococci and severe disease in children. Pediatr Infect Dis J 1991; 10: 351–4
Shulman ST. Invasive and toxin-related diseases caused by group A streptococci. Pediatr Infect Dis J 1991; 10 Suppl. 10: S28–31
Marrack P, Kappler J. The streptococcal enterotoxins and their relatives. Science 1990; 248: 705–11
Report of a WHO study Group. Rheumatic fever and rheumatic heart disease. Bull Int Pediatr Assoc 1988; 166–213
Rammelkamp CH, Wannamaker LW, Denny FW. The epidemiology and prevention of rheumatic fever. Bull NY Acad Med 1952; 28: 321–34
Wannamaker LW. Changes and changing concepts in the biology of Group A streptocci and in the epidemiology of streptococcal infections. Rev Infect Dis 1979; 1: 967–75
Brennan RE, Patel MS. Acute rheumatic fever and rheumatic heart disease in a rural central Australian Aboriginal community. Med J Aust 1990; 153: 335–9
Taneja V, Mehra NK, Reddy KS, et al. HLA-DQ/DR antigens and reactivity to B cell alloantigen D8/17 in Indian patients with rheumatic heart disease. Circulation 1989; 80: 335–40
Rajapakse CNA, Halim K, Al-Orainey I, et al. A genetic marker for rheumatic heart disease. Br Heart J 1987; 58: 659–62
Ayoub EM, Barrett J, Maclaren MK, et al. Association of class II human histocompatibility leukocyte antigens with rheumatic fever. J Clin Invest 1986; 77: 2019–26
Guilherme L, Weidebach W, Kiss MH, et al. Association of human leukocyte class II antigens with rheumatic fever or rheumatic heart disease in a Brazilian population. Circulation 1991; 83: 1995–8
Stastny P. Association of the B cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978; 298: 869–71
Solingar AM, Bhatnager R, Stobo JD. Cellular, molecular and genetic characteristics of T cell reactivity to collagen in man. Proc Natl Acad Sci USA 1981; 78: 3877–8
Rajapakse C, Al Balla S, Al-Dallan A, et al. Streptococcal antibody cross-reactivity with HLA-DR4 positive B-lymphocytes. Basis of the DR4 associated genetic predisposition to rheumatic fever and rheumatic heart disease? Br J Rheumatol 1990; 29: 468–70
Layrisse Z, Rodriguez I, Garcia Ramirez R, et al. Family studies in HLA system in acute streptococcal glomerulonephritis. Immunology 1983; 7: 177–85
Ayoub EM. The search for genetic determinants of susceptibility to rheumatic fever: the missing link. Circulation 1984; 69: 197–201
Zabriskie JB. Rheumatic fever: a model for the pathological consequences of microbial-host mimicry. Clin Exp Rheumatol 1986; 4: 65–73
Patarroyo ME, Winchester RJ, Vejerano A, et al. Associations of a B cell alloantigen with susceptibility to rheumatic fever. Nature 1979; 278: 173–4
Zabriskie JB, Lavenchy D, Fu SM, et al. The use of monoclonal antibodies to detect the presence of two B cell alloantigens in rheumatic fever patients. Arthritis Rheum 1985; 28: 1047–51
Gray ED, Regelmann WE, Abdin ZH, et al. Compartmentalization of cells bearing ‘rheumatic’ cell surface antigens in peripheral blood and tonsils in rheumatic heart disease. J Infect Dis 1987; 155: 247–52
Regelmann WE, Talbot R, Cairns L, et al. Distribution of cells bearing ‘rheumatic’ antigens in peripheral blood of patients with rheumatic fever/rheumatic heart disease. J Rheumatol 1989; 16: 931–5
Hafez M, El-Battoty MF, Hawas S, et al. Evidence of inherited susceptibility of increased adherence to pharyngeal cells of children with rheumatic fever. Br J Rheumatol 1989; 28: 304–9
Read SE, Reid HF, Fischetti VA, et al. Serial studies on the cellular immune response to streptococcal antigens in acute convalescent rheumatic fever patients in Trinidad. J Clin Immunol 1986; 6: 433–41
Gray ED, Abdin ZH, El Kholy A, et al. Augmentation of cytotoxic activity by mitogens in rheumatic heart disease. J Rheumatol 1988; 15: 1672–6
Miller LC, Gray ED, Mansour M, et al. Cytokines and immunoglobulin in rheumatic heart disease: production by blood and tonsillar mononuclear cells. J Rheumatol 1989; 16: 1436–42
Hafez M, El-Shannawy F, El-Salab S, et al. Studies of peripheral blood lymphocytes in assessment of disease activity in rheumatic fever. Br J Rheumatol 1988; 27: 181–6
Alarcon-Riquelme ME, Alarcon-Segovia AD, Loredo-Abdala A, et al. T lymphocyte subsets, suppressor and contrasuppressor cell functions, and production of interleukin-2 in the peripheral blood of rheumatic fever patients and their apparently healthy siblings. Clin Immunol Immunopathol 1990; 55: 120–8
Zedan MM, El-Shennawy FA, Abou-Bakr HM, et al. Interleukin-2 in relation to T cell subpopulation in rheumatic heart disease. Arch Dis Child 1992; 67: 1373–5
Cairns LM. Immunological studies in rheumatic fever. The immunology of rheumatic fever. NZ Med J 1988; 101: 388–91
Hafez M, Abdalla A, El-Shennawy F, et al. Immunogenetic study of the response to streptococcal carbohydrate antigen of the cell wall in rheumatic fever. Ann Rheum Dis 1990; 49: 708–14
Murphy GE. The characteristic rheumatic lesions of striated and of non-striated or smooth muscle cells of the heart: genesis of the lesions known as Aschoff bodies and those myogenic components known as Aschoff cells or as Anitschkow cells or myocytes. Medicine 1963; 42: 73–117
Raizada V, Williams R, Chopra P, et al. Tissue distribution of lymphocytes in rheumatic heart valves as defined by monoclonal anti-T cell antibodies. Am J Med 1983; 74: 90–6
Narula J, Chopra P, Talwar KK, et al. Histomorphological and immunohistochemical studies in acute rheumatic myocarditis in man: a prospective endomyocardial biopsy study. Circulation 1988; 78 Suppl. 11: 440
Husby G, Arora R, Williams RC, et al. Immunofluorescence studies of florid rheumatic Aschoff lesions. Arthritis Rheum 1986; 29: 207–11
Amoils B, Morrison RC, Wades AA, et al. Aberrant expression of HLA-DR antigen on valve fibroblasts from patients with active rheumatic carditis. Clin Exp Immunol 1986; 66: 88–94
World Health Organization. Rheumatic fever and rheumatic heart disease. Report of a WHO Study Group. WHO Technical Report Series 764, Geneva, 1988: 5–58
Gerber MA, Spadaccini LJ, Weight LL, et al. Latex agglutination tests for rapid identification of Group A streptococci directly from throat swabs. J Pediatr 1984; 105: 702–9
Campos JM, Charilaou CC. Evaluation of Detect-a-strep with the culturette ten-minute Strep ID kits for detection of Group A streptoccal antigen in oropharyngeal swabs from children. J Clin Microbiol 1985; 22: 145–8
Redd SC, Facklam RR, Collins S, et al. Rapid group A streptococcal antigen detection kit: effect on antimicrobial therapy for acute pharyngitis. Pediatrics 1988; 82: 576–81
Dajani AS, Bisno AL, Chung KJ, et al. Prevention of rheumatic fever: a statement for health professionals by the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Circulation 1988; 78: 1082–6
Pichichero ME, Margolis PA. A comparison of cephalosporins and penicillins in the treatment of group A beta-hemolytic streptococcal pharyngitis: a meta-analysis supporting the concept of microbial copathogenicity. Pediatr Infect Dis J 1991; 10: 272–81
Pichichero ME. Cephalosporins are superior to penicillin for treatment of streptococcal tonsillopharyngitis: is the difference worth it? Pediatr Infect Dis J 1993; 12: 268–74
Grahn E, Holm SE, Roos K. Penicillin tolerance in beta-streptococci isolated from patients with tonsillitis. Scand J Infect Dis 1987; 19: 421–6
Dagan R, Ferne M, Sheinis M, et al. An epidemic of penicillin-tolerant group A streptococcal pharyngitis in children living in a closed community: mass treatment with erythromycin. J Infect Dis 1987; 156: 514–6
Maruyama S, Yoshioka H, Fujita K, et al. Sensitivity of group A streptococci to antibiotics: prevalence of resistance to erythromycin in Japan. Am J Dis Child 1979; 133: 1143–5
Seppala H, Nissinen A, Jarvinen H, et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992; 326: 292–7
Community control of rheumatic heart disease in developing countries: 2. Strategies for prevention and control. WHO Chron 1980; 34: 389–95
Padmavati S, Gupta V, Prakash K, et al. Penicillin for rheumatic fever prophylaxis: 3-weekly or 4-weekly schedule? J Assoc Physicians India 1987; 35: 753–5
Hung-Chi L, Lei-Hwan W, Kue-Hsiung H. Rheumatic fever recurrences: controlled study of 3-weekly versus 4-weekly benzathine penicillin prevention programs. J Pediatr 1986; 108: 299–304
Kaplan EL, Berrios X, Speth J, et al. Pharmacokinetics of benzathine penicillin G: serum levels during the 28 days after intramuscular injection of 1,200,000 units. J Pediatr 1989; 115: 146–50
Boxerbaum B. Prevention of rheumatic fever. J Pediatrics 1990; 117: 842
Meira ZM, Mota Cde C, Tonelli E, et al. Evaluation of secondary prophylactic schemes, based on benzathine penicillin G, for rheumatic fever in children. J Pediatr 1993; 123: 156–8
Homer C, Shulman ST. Clinical aspects of acute rheumatic fever. J Rheumatol 1991; 18 Suppl. 29: 2–13
Haffejee IE. Penicillin prophylaxis for rheumatic fever: time for national action. Cardiovasc J South Afr 1994; 5: 47–48
Talbot RG. Rheumatic fever in the Hamilton health district: a nine year prospective study. NZ Med J 1988; 101: 406–8
World Health Organization. Streptococcal/Rheumatic Fever Newsletter 1989; 3: 1–4
Iyengar SD, Grover A, Kumar R, et al. Participation of health workers, school teachers and pupils in the control of rheumatic fever: evaluation of a training programme. Indian Pediatr 1992; 29: 875–81
Poirier TP, Kehoe MA, Beachey EH. Protective immunity evoked by oral administration of attenuated aro A Salmonella typhimurium expressing cloned streptococcal M protein. J Exp Med 1988; 168: 25–32
Fischetti VA, Hodges WM, Hruby DE. Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant. Science 1989; 244: 1487–90
Beachey EH, Seyer JM, Dale JB. Protective immunogenicity and T lymphocyte specificity of a trivalent hybrid peptide containing NH2-terminal sequences of types 5, 6, and 24 M proteins synthesized in tandem. J Exp Med 1987; 166: 647–56
Antibiotic prophylaxis of infective endocarditis. Recommendations from the Endocarditis Working Party of the British Society for Antimicrobial Chemotherapy. Lancet 1990; 335: 88–9
Van der Meer JT, Van Wijk W, Thompson J, et al. Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis. Lancet 1992; 339: 135–9
Behrman RE, Kliegman RM, Nelson WE, et al., editors. Nelson Textbook of Pediatrics. 14th ed. Philadelphia: WB Saunders Co, 1992: 640–6
Wannamaker LW, Kaplan WL. Acute rheumatic fever. In: Moss AS, Adams F, Emanouilides GC, editors. Heart disease in infants, children and adolescents. 2nd ed. Baltimore: Williams and Wilkins, 1977: 515–32
Haffejee IE, Moosa A. A double-blind placebo-controlled trial of prednisone in active rheumatic carditis. Ann Trop Paediatr 1990; 10: 395–400
Bruwer AD. Vasodilators in the management of heart failure in children. Specialist Med 1994; 16: 24–30
Schneeweiss A. Cardiovascular drugs in children. II. Angiotensin-converting enzyme inhibitors in pediatric patients. Pediatr Cardiol 1990; 11: 199–207
Barlow JB, Marcus RH, Pocock WA, et al. Mechanisms and management of heart failure in active rheumatic carditis. S Afr Med J 1990; 78: 191–86
Chauvand S, Perier P, Touati G, et al. Long-term results of valve repair in children with acquired mitral valve incompetence. Circulation 1986; 74 Suppl. 1: 1–104
Marcus RH, Sareli P, Pocock WA, et al. Functional anatomy of severe mitral regurgitation in active rheumatic carditis. Am J Cardiol 1989; 63: 577–84
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haffejee, I.E. Rheumatic Heart Disease. Clin Immunother 4, 72–82 (1995). https://doi.org/10.1007/BF03259072
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259072